| Biomarker ID | 1443 |
| PMID | 24909936 |
| Year | 2014 |
| Biomarker | MUC1 + p53+ AZGP1 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Increased with Increased mortality |
| Odds Ratio/Hazard Ratio/Relative Risk | Mortality Rate Ratios: MRR: [MUC1: 2.10 (95% CI: 0.94, 4.69)]; p53: [2.76 (95% CI: 1.23- 6.20)]; AZGP1: [0.47 (95% CI: 0.20-1.08)]; |
| Effect on Pathways | NA |
| Experiment | PCa Specific Mortality Vs No Mortality |
| Type of Biomarker | Prognostic |
| Cohort | Subjects were identified from three Australian epidemiological studies. Men who had died of their disease, “cases†(N = 83), were matched to “referents†(N = 232), those who had not died of prostate cancer, using incidence density sampling. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |